Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) FCF Margin (2020 - 2025)

Historic FCF Margin for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to 231.33%.

  • Foghorn Therapeutics' FCF Margin rose 416500.0% to 231.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 362.49%, marking a year-over-year increase of 446900.0%. This contributed to the annual value of 448.24% for FY2024, which is 988700.0% down from last year.
  • Per Foghorn Therapeutics' latest filing, its FCF Margin stood at 231.33% for Q3 2025, which was up 416500.0% from 278.18% recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' FCF Margin ranged from a high of 6920.59% in Q1 2022 and a low of 50565.85% during Q3 2021
  • Its 5-year average for FCF Margin is 3382.02%, with a median of 478.04% in 2023.
  • Its FCF Margin has fluctuated over the past 5 years, first tumbled by -490580300bps in 2021, then surged by 502596100bps in 2022.
  • Foghorn Therapeutics' FCF Margin (Quarter) stood at 1655.26% in 2021, then crashed by -142bps to 697.73% in 2022, then surged by 31bps to 478.04% in 2023, then crashed by -83bps to 875.28% in 2024, then soared by 74bps to 231.33% in 2025.
  • Its last three reported values are 231.33% in Q3 2025, 278.18% for Q2 2025, and 403.16% during Q1 2025.